GBT-201: Phase III started

ReGenTree LLC began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate RGN-259 given 5 times daily for 28 days in about 46 patients with chronic stage 2 or 3 neurotrophic keratitis. ...